Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10111390 | 0.86 | USP2 (0.41) | NAMPTHDAC1HDAC8HDAC6GPR119 | |
| SCHEMBL21068409 | 0.80 | CYP2D6 (0.43) | NAMPTHDAC1GPR119HDAC2CYP11B2 | |
| SCHEMBL3495197 | 0.80 | USP2 (0.42) | NAMPTGPR119CYP11B2ACACBUSP2 | |
| SCHEMBL31116711 | 0.79 | CYP2D6 (0.45) | HDAC1GPR119HDAC2CYP11B2ACACB | |
| SCHEMBL2695429 | 0.79 | HDAC1 (0.53) | NAMPTHDAC1HDAC8HDAC6ITGB3 | |
| SCHEMBL29921574 | 0.78 | CYP11B2 (0.44) | NAMPTHDAC1GPR119HDAC2ITGB3 | |
| SCHEMBL25967353 | 0.78 | USP2 (0.43) | NAMPTHDAC1GPR119HDAC2ITGB3 | |
| SCHEMBL21068971 | 0.78 | CYP2D6 (0.50) | NAMPTGPR119USP2SMN1; SMN2 | |
| SCHEMBL12447685 | 0.78 | OPRD1 (0.51) | HDAC1HDAC8HDAC6GPR119CYP11B2 | |
| SCHEMBL22770534 | 0.78 | ALDH1A1 (0.46) | HDAC1HDAC8HDAC6GPR119USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| WO-2010129729-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041012-A1 | SUBSTITUTED SPIROCYCLIC AMINES USEFUL AS ANTIDIABETIC COMPOUNDS | SSTR5, SSTR2, GPR119 | NAMPT 3431/4885HDAC1 808/4885HDAC8 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.